Abstract
Multiple myeloma SET domain (MMSET) has been shown to be overexpressed in many different cancer tissues. Our study was to investigate the expression of MMSET in serous ovarian carcinoma and to evaluate its clinical significance in patients with serous ovarian carcinoma. Immunohistochemistry was performed to determine the expression of MMSET in 132 serous ovarian carcinoma, 32 normal ovarian and fallopian tube specimens. The high expression of MMSET was observed in 49.2% (65/132) in patients with serous ovarian carcinoma. MMSET high expression correlated with the advanced extent of serous ovarian carcinoma and poor outcome. MMSET may serve as a new molecular marker to predict the prognosis of serous ovarian carcinoma in the clinic.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Biomarkers, Tumor / genetics*
-
Biomarkers, Tumor / metabolism
-
Cystadenocarcinoma, Serous / diagnosis
-
Cystadenocarcinoma, Serous / genetics*
-
Cystadenocarcinoma, Serous / mortality
-
Cystadenocarcinoma, Serous / pathology
-
Female
-
Gene Expression
-
Histone-Lysine N-Methyltransferase / genetics*
-
Histone-Lysine N-Methyltransferase / metabolism
-
Humans
-
Immunohistochemistry
-
Middle Aged
-
Neoplasm Grading
-
Neoplasm Staging
-
Ovarian Neoplasms / diagnosis
-
Ovarian Neoplasms / genetics*
-
Ovarian Neoplasms / mortality
-
Ovarian Neoplasms / pathology
-
Ovary / metabolism
-
Ovary / pathology
-
Prognosis
-
Repressor Proteins / genetics*
-
Repressor Proteins / metabolism
-
Survival Analysis
Substances
-
Biomarkers, Tumor
-
Repressor Proteins
-
Histone-Lysine N-Methyltransferase
-
NSD2 protein, human